Autolus Therapeutics Announces Positive Clinical Data for Obe-cel CAR T Therapy at ASH 2025
Reuters
Nov 03, 2025
Autolus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Clinical Data for Obe-cel CAR T Therapy at ASH 2025
Autolus Therapeutics plc has announced the upcoming presentation of new clinical data at the American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The company will present results from multiple studies, including initial safety and preliminary efficacy data from the Phase I CARLYSLE study of obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-cell therapy, in patients with severe, refractory systemic lupus erythematosus. Additional presentations will cover the impact of CAR product cell phenotypes on outcomes in acute lymphoblastic leukemia $(ALL)$, and preliminary findings from the Phase Ib/II CATULUS trial evaluating obe-cel in pediatric patients with relapsed or refractory B-cell ALL. The results will be presented at the ASH Annual Meeting and have not yet been publicly disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567156-en) on November 03, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.